Bladder Cancer | Tumor

Announcing BCAN 2020 Young Investigator Awards

January 11th 2020

The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.

What You Need to Know About the FDA's Approval of Keytruda in High-Risk NMBIC

January 11th 2020

This new option may save patients with high-risk non-muscle invasive bladder cancer from having to undergo a radical cystectomy to treat their disease.

Bladder Cancer Advocacy Network Turns 15

January 10th 2020

At 15 years old the Bladder Cancer Advocacy Network looks back and takes a look ahead.

FDA Approves Keytruda for High-Risk, Non-Muscle Invasive Bladder Cancer

January 9th 2020

The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.

Phase 3 Interim Analysis Shows Improved Survival in Patients with Bladder Cancer

January 7th 2020

Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.

What You Need to Know About the FDA's Approval of Padcev to Treat Bladder Cancer

December 28th 2019

The Food and Drug Administration’s accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.

I Dodged a Bullet

December 26th 2019

FDA Approves Padcev to Treat Bladder Cancer

December 19th 2019

The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

FDA Grants Priority Review to Keytruda for Non-Muscle Invasive Bladder Cancer

December 3rd 2019

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.

First-Line Tecentriq Plus Chemo Shows Promise in Metastatic Bladder Cancer

October 10th 2019

The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.

Newly Approved Targeted Therapy Paves the Way for Patients With Advanced Bladder Cancer

September 14th 2019

The oral medication Balversa (erdafitinib) shows promise in patients who have FGFR3 gene alterations.

CURE's Top 5 Stories: July 2019

August 1st 2019

Here are the top 5 CURE stories for July 2019.

Rapid Autopsy Offers New Insights into Advanced Bladder Cancer Research and Treatment

July 22nd 2019

Genomic distinctions between bladder cancer variances are revealed through rapid autopsy, according to one study, and may help push forward bladder cancer research.

How One Patient Turned Caregiver Leaves No Stone Unturned

July 18th 2019

Karen, who received her bladder cancer diagnosis in 2010, was faced with a similar challenge after her husband was diagnosed with the same disease just six years later.

From Patient to Cancer Caregiver

July 11th 2019

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a bladder cancer survivor turned caregiver about the advice she would give her newly-diagnosed self.

Practice-Changing Treatments for Bladder Cancer

July 10th 2019

A medical oncologist discusses the findings of three clinical trials presented during the 2019 American Society of Clinical Oncology Annual Meeting.

Bladder Cancer Advocacy Network Announces 2019 Bladder Cancer Research Innovation Awardee

July 8th 2019

The Bladder Cancer Advocacy Network announced the recipient of its prestigious Bladder Cancer Research Innovation Award.

Immunotherapy Combo Improves Responses in Patients With Metastatic Bladder Cancer

June 5th 2019

Compared with single-agent therapy, the combination of Yervoy and Opdivo showed a 38% overall response rate.

New Targeted Antibody Shows Promise for Advanced Urothelial Cancer

June 3rd 2019

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

Friday Frontline: May 31, 2019

May 31st 2019

From today’s top performers to the latest in scientific research, here’s what is making headlines in the cancer space this week.

Friday Frontline: May 24, 2019

May 24th 2019

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

Non-Invasive Urine Tests Show Promise in Bladder Cancer Detection, Monitoring

May 17th 2019

With no available diagnostic tests for the detection and/or monitoring of bladder cancer, researchers from the Medical College of Georgia at Augusta University may have two new urine tests that determine the disease’s severity and detect for its recurrence.

Bladder Cancer Awareness Month: Understanding Risk for Earlier Detection

May 16th 2019

May is recognized as Bladder Cancer Awareness Month. Know the facts and statistics in order to understand your risk for the disease and take preventative actions to guard your health.

Smoking Cessation Programs Help Reduce Bladder Cancer Risk in Older Women

May 15th 2019

A recent study showed that postmenopausal women demonstrated a significant reduction in the risk for bladder cancer after quitting smoking, highlighting the need for prevention and cessation programs in older women.

Genomic Profiling May Translate to Personalized Treatment for Bladder Cancer Subtypes

May 14th 2019

Researchers at Baylor College of Medicine found that a particular subgroup of patients with advanced bladder cancer, identified with a computational tool, responded to immunotherapy.

The Role of Mental Health in Cancer Outcomes

April 24th 2019

A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.

Age at Menopause May Play a Role in Bladder Cancer Risk

April 16th 2019

Researchers found that women who went into menopause before 45 years old were at greater risk for bladder cancer than women who experienced it later.

Updates to Bladder Cancer Treatment Guidelines Offer Hope

April 16th 2019

After more than 30 years of relative stability, the treatment landscape for urothelial cancer has seen updates in recent years that provide hope for patients.

Non-Muscle Invasive Bladder Cancer Survivors Experience PTSD Symptoms

April 12th 2019

According to survey results, almost 30% of non-muscle invasive bladder cancer survivors experienced at least one PTSD symptom.

FDA Approves First Targeted Therapy to Treat Metastatic Bladder Cancer

April 12th 2019

The Food and Drug Administration granted accelerated approval to Balversa to treat locally advanced or metastatic bladder cancer with a type of susceptible genetic alterations known as FGFR3 or FGFR2, in patients who have progressed during or following prior platinum-containing chemotherapy.